282 related articles for article (PubMed ID: 35257287)
1. Targeted Drug Delivery for Chronic Lymphocytic Leukemia.
Zoulikha M; He W
Pharm Res; 2022 Mar; 39(3):441-461. PubMed ID: 35257287
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. [Research Progress in Treatment of Chronic Lymphocytic Leukemia --Review].
Zhang R; Xin R; Dou LP; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1910-1915. PubMed ID: 38071082
[TBL] [Abstract][Full Text] [Related]
5. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia (CLL)-Then and now.
Rai KR; Jain P
Am J Hematol; 2016 Mar; 91(3):330-40. PubMed ID: 26690614
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
[TBL] [Abstract][Full Text] [Related]
9. Chronic lymphocytic leukemia.
Byrd JC; Stilgenbauer S; Flinn IW
Hematology Am Soc Hematol Educ Program; 2004; ():163-83. PubMed ID: 15561682
[TBL] [Abstract][Full Text] [Related]
10. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies.
Kojima K; Burger JA
J Clin Exp Hematop; 2020 Dec; 60(4):130-137. PubMed ID: 32404571
[TBL] [Abstract][Full Text] [Related]
11. Biology and treatment of chronic lymphocytic leukemia.
Keating MJ; Chiorazzi N; Messmer B; Damle RN; Allen SL; Rai KR; Ferrarini M; Kipps TJ
Hematology Am Soc Hematol Educ Program; 2003; ():153-75. PubMed ID: 14633781
[TBL] [Abstract][Full Text] [Related]
12. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients.
da Cunha-Bang C; Simonsen J; Rostgaard K; Geisler C; Hjalgrim H; Niemann CU
Blood Cancer J; 2016 Nov; 6(11):e499. PubMed ID: 27834937
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for chronic lymphocytic leukemia: current status and future directions.
Arnason JE; Brown JR
Drugs; 2015 Feb; 75(2):143-55. PubMed ID: 25619739
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
15. Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia.
Darwiche W; Gomila C; Ouled-Haddou H; Naudot M; Doualle C; Morel P; Nguyen-Khac F; Garçon L; Marolleau JP; Ghamlouch H
J Exp Clin Cancer Res; 2020 Oct; 39(1):228. PubMed ID: 33115525
[TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer L; Egle A; Hartmann TN; Greil R
Nat Rev Clin Oncol; 2009 Jul; 6(7):405-18. PubMed ID: 19488076
[TBL] [Abstract][Full Text] [Related]
17. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
19. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Wendtner CM; Gregor M
Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
